ArriVent Lung Cancer Treatment Fails Late-Stage Trial
ArriVent BioPharma announced that its therapy for a specific type of lung cancer did not achieve its primary objective in a late-stage clinical trial.
Story updates
12:08:03 PM UTC
SquawkNews
ArriVent said the Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC did not meet its primary PFS endpoint by BICR. Secondary endpoints showed clinical benefit, and an immature trend toward improved OS was observed; safety was consistent.Material DetailsContext by AI…
12:13:19 PM UTC
SquawkNews
ArriVent reported that its Phase 3 FURVENT trial of firmonertinib did not meet the primary PFS endpoint by blinded independent central review.Key Highlights:Original SEC Filing: ArriVent BioPharma, Inc. [ AVBP ] - 8-K - Oct. 06, 2026This is an AI-powered summary. It may contain inaccuracies. Consid…
ArriVent BioPharma said on Tuesday its therapy for patients with a type of lung cancer did not meet the main endpoint in a late-stage trial.